Cipla's RT-PCR Test Kit 'ViraGen' To Be Sold From Today
Updated On Jul 05, 2021
According to Cipla Limited, the pharmaceutical major company in India, its RT-PCR test kit, launched last week, will be available in the market from May 25 onwards. The RT-PCR test kit is manufactured by Cipla Limited in partnership with Ubio Biotechnology Systems. The RT-PCR kit is called 'ViraGen'.
It must be noted that ‘ViraGen’ is a real-time detection kit, which has gained approval from the ICMR (Indian Council of Medical Research). The kit is based on multiplex PCR technology. ‘ViraGen’ will allow identification and detection of SARS CoV-2 N Gene and ORF Lab Gene. The kit will have a sensitivity of 98.6% and a specificity of 98.8% in comparison to a standard ICMR test as per BioSpectrum magazine's website.
As per Cipla, ‘ViraGen’ has been specifically designed for the first-rate detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from people suspected of COVID-19 infection.
'ViraGen' is Cipla Limited’s third testing kit for COVID-19 infection. It must be noted that Cipla is already in partnership for antigen test kits and antibody detection kits. It launched the ‘CIPtest’ rapid antigen test in December 2020. Earlier, in October 2020, Cipla had launched the 'Elifast: SARS CoV-2 IgG ELISA' test kit.
In a regulatory filing, Cipla informed that the launch will support in addressing the testing services and capacity issues at the present time while reaffirming Cipla’s ongoing expansion in the field of diagnostics.
Umang Vohra, MD and Global CEO, Cipla, reportedly stated that the company has been working consistently to ensure accessibility to treatments against the deadly COVID-19 infection. He added that the firm’s partnership with Ubio Biotechnology Systems will help both reach the maximum number of people in the trying times of the coronavirus pandemic.
You may also like to read:
Disclaimer: This article is issued in the general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.